IN THE CLAIMS:

The status of the claims is as follows:

Claims 1-39. (Cancelled).

Claim 40. (Previously Presented) A pharmaceutical composition useful for treating an immunosuppressive disease comprising:

(A) a pharmaceutically effective amount of a cAMP antagonist, wherein said cAMP antagonist is selected from the group consisting of Rp-8-Br-cAMPS, Rp-8-Br-monobutyryl-cAMPS, Rp-monobutyryl-cAMPS, Rp-8-(4-chlorophenyl-thio)-cAMPS and Rp-piperidino-cAMPS; and

(B) a pharmaceutically acceptable adjuvant or filler.

Claim 41. (Previously Presented) The pharmaceutical composition according to Claim 40, wherein said cAMP antagonist is Rp-8-Br-cAMPS.

Claim 42. (Previously Presented) The pharmaceutical composition according to Claim 40, wherein said immunosuppressive disease is selected from the group consisting of AIDS, HIV infection and CVI.

Claim 43. (Currently Amended) A method of inhibiting the effects mediated by PKA type Iα isozyme comprising administering to a subject in need of said inhibition, a pharmaceutical composition comprising:

(A) a pharmaceutically effective amount of a cAMP antagonist, wherein said cAMP antagonist is selected from the group consisting of Rp-8-Br-cAMPS, Rp-8-Br-monobutyryl-cAMPS,

Rp-monobutyryl-cAMPS, Rp-8-(4-chlorophenyl-thio)-cAMPS and Rp-piperidino-cAMPS; and

(B) a pharmaceutically acceptable adjuvant or filler.

Claim 44. (Previously Presented) The method according to Claim 43, wherein said cAMP antagonist is Rp-8-Br-cAMPS.

Claim 45. (Currently Amended) A method of treating a subject afflicted with an immunosuppressive disease selected from the group consisting of AIDS, HIV infection and CVI, comprising administering to said subject a pharmaceutical composition comprising:

(A) a pharmaceutically effective amount of a cAMP antagonist sufficient to treat an immunosuppressive disease selected from the group consisting of AIDS, HIV infection and CVI, wherein said cAMP antagonist selectively or specifically abolishes the function of cAMP dependent protein kinase (PKA) type Iα isozyme ($RI\alpha_2C_2$); and

(B) a pharmaceutically acceptable adjuvant or filler.

Claim 46. (Cancelled).

Claim 47. (Previously Presented) The method of Claim 45, wherein said cAMP antagonist is a thio-substituted cAMP analog, wherein said thio-substituted cAMP analog is an equatorial diastereomer of 3',5'-cyclic adenosine monophosphorothioate (Rp-cAMPS), and wherein said thio-substituted cAMP analog binds to an RIα subunit of said isozyme and acts as a selective or specific antagonist of said isozyme.

Claim 48. (Previously Presented) The method of Claim 47, wherein said cAMP antagonist is selected from the group consisting

of Rp-8-Br-cAMPS, Rp-8-Br-monobutyryl-cAMPS, Rp-monobutyryl-cAMPS, Rp-8-(4-chlorophenyl-thio)-cAMPS, Rp-piperidino-cAMPS, and Rp-8-Cl-cAMPS.

Claim 49. (Previously Presented) The method of Claim 48, wherein said cAMP antagonist is selected from the group consisting of Rp-8-Br-cAMPS and Rp-8-Cl-cAMPS.

Claim 50. (Cancelled).

Claim 51. (New) The method of Claim 47, wherein said cAMP antagonist is a Rp-8 substituted cAMPS.